Beta Bionics (BBNX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Beta Bionics (BBNX) is a US-listed Healthcare company in Medical - Equipment & Services with a market capitalization of $742M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beta Bionics's market cap?
Beta Bionics (BBNX) has a market capitalization of approximately $742M, trading at
What is Beta Bionics's P/E ratio?
Beta Bionics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beta Bionics?
Beta Bionics runs a net profit margin of -60.3%, a gross margin of 57.2%, and an operating margin of -70.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beta Bionics generate?
Beta Bionics reported revenue of
Does Beta Bionics pay a dividend?
Beta Bionics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Beta Bionics financially healthy?
Beta Bionics carries a debt-to-equity ratio of 0.03x and a current ratio of 10.69x, with a market beta of 3.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beta Bionics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beta Bionics (BBNX) the key facts are: market cap $742M, revenue
Track Beta Bionics's full fundamentals live
Get Beta Bionics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.